Investigación - Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud

Seguimos avanzando en investigación. Nuestro Instituto ha recibido su primera patente para el desarrollo de tratamientos con células mesenquimales.

Los productos medicinales de terapia avanzada son una nueva generación de productos terapéuticos para el tratamiento efectivo de enfermedades complejas y de alto impacto. La Unidad de Terapias Avanzadas (UTA) del IDCBIS viene liderando el avance de este importante campo de la biotecnología a partir de la implementación de capacidades científicas y tecnológicas para generar medicinas mas costo-efectivas que resuelvan problemas específicos en salud de la población.

En este proceso, la UTA desarrolla diferentes innovaciones que incluyen nuevos métodos para la producción biofarmacéutica de productos de terapia avanzada, que en la actualidad se encuentran en procesos de protección intelectual. En ese sentido la Superintendencia de Industria y Comercio concedió la primera patente al IDCBIS denominada “Método de estimulación de células estromales mesenquimales para inducir expresión de factores inmunomoduladores”, una tecnología desarrollada por investigadores de la UTA.

Con esta tecnología se pueden generar productos medicinales para tratar enfermedades que por su componente altamente inflamatorio, causan la degeneración y pérdida de función de diferentes tejidos y órganos. La patente concede la propiedad al IDCBIS sobre una nueva metodología para la producción de este tipo de medicamentos a partir de la potenciación del efecto antiinflamatorio de células estromales mesenquimales, como principio activo de estos nuevos medicamentos biotecnológicos.

Con este logro, el IDCBIS se posiciona en el sector de investigación e innovación biotecnológico como centro de desarrollo de terapias avanzadas para el servicio del sector salud en el Distrito y el país.

¡Buenas noticias para Bogotá y toda Colombia! El Banco Distrital de Sangre del IDCBIS ha obtenido la certificación más prestigiosa en calidad para los bancos de sangre a nivel internacional. La Fundación CAT, reconocida entidad de certificación en transfusión, terapia celular y tisular de España, ha otorgado a esta institución de salud una acreditación que garantiza la excelencia en sus prestaciones médicas.

Este logro trascendental coloca al Banco Distrital de Sangre IDCBIS en un lugar destacado no solo a nivel nacional, sino también como referente internacional en bancos de sangre y servicios de transfusión. Nuestra entidad ha demostrado su compromiso inquebrantable con la calidad y la seguridad al ser el único banco en el país que realiza pruebas de biología molecular (NAT) al 100% de los componentes sanguíneos para garantizar la seguridad en las transfusiones.

La acreditación CAT, que se renueva cada cuatro años, destaca la excelencia en medicina transfusional que el Banco Distrital de Sangre IDCBIS ofrece a la sociedad. Tanto los donantes como los pacientes que reciben los hemocomponentes de este banco se benefician de la seguridad y calidad garantizada por esta certificación.

El Dr. Bernardo Camacho, director del IDCBIS, expresó su satisfacción al recibir la noticia: “Nos complace anunciar a la comunidad científica, académica, sanitaria y a la sociedad, la obtención de esta certificación internacional en calidad para nuestro Banco Distrital de Sangre. Cumplimos con los más altos estándares de calidad europeos en la captación, procesamiento y distribución de los hemocomponentes”.

Esta certificación no solo enaltece al Banco Distrital de Sangre IDCBIS, sino que también posiciona a Bogotá como un referente en calidad en medicina transfusional, generando reconocimiento y confianza en los productos y servicios de salud ofrecidos a la población. El compromiso de nuestra institución con la seguridad y calidad de las donaciones es evidente en sus estrictos protocolos y estándares internacionales, lo que garantiza que cada donante experimente un proceso seguro y cómodo.

Le puede interesar: Una donación, cuatro bebés beneficiados

Con este logro, los pacientes que dependen de transfusiones sanguíneas pueden tener la tranquilidad de recibir componentes de la más alta calidad y seguridad.

En resumen, el Banco Distrital de Sangre IDCBIS ha alcanzado un hito excepcional al obtener la certificación CAT, consolidando su liderazgo en la medicina transfusional y proyectando a Bogotá como una ciudad comprometida con la excelencia en el cuidado de la salud de sus ciudadanos. Esta noticia nos llena de orgullo y confianza en el sistema de salud de nuestra ciudad y país.

¡Felicidades al Banco Distrital de Sangre IDCBIS por este logro sobresaliente en beneficio de toda la comunidad!

The District strengthens health research with the cooperation agreement between the Universidad Nacional de Colombia - Bogotá and the Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud.

Seminar on Health Research 2022: dialogues between research, academia and institutions to make visible, relate, recognize and establish possible strategic alliances around health research.

August 9, 2022. The agreement between the two institutions has a duration of 5 years and seeks to create a framework for scientific cooperation to advance joint actions in the areas of training, research, extension, technical, administrative and academic assistance, which allow the institutional strengthening of both entities. After only seven months of having started to implement the agreement, 3 projects have already been submitted to calls for proposals from the Ministry of Science, Technology and Innovation - Minciencias.

The National University of Colombia - Bogotá campus is a national leader in higher education and research according to the U-Sapiens Ranking, recognized for its contribution to the nation and for its excellence in training, research, and social and technological innovation processes.

For its part, IDCBIS has established itself as an institution of reference in the country, achieving recognition as a research center by the Ministry of Science, Technology and Innovation under Resolution 1763 of 2021, demonstrating the ability of IDCBIS to generate high impact products, relevant to the scientific and academic society, and to society in general.

An important point of this agreement is the development of the 2022 Health Research Seminar, which opened the door for all those interested to access spaces led by experts, with the participation of 37 researchers and the attendance of more than 900 people in the five cycles.

Topics related to the health area were discussed, such as: predictive and personalized medicine, cellular therapies, neurodegenerative and rheumatologic diseases, population genetics and social appropriation of knowledge.

This space was an opportunity to establish dialogues between research, academia and institutions, contributing to the objective of making visible, relating, recognizing and establishing possible strategic alliances.

About IDCBIS:

The District Institute of Science, Biotechnology and Innovation in Health is a research center linked to the Health Sector of the Capital District. It promotes the advancement of health sciences, biotechnological research, the provision of biological supplies and the training of human resources in transfusion medicine, advanced tissue and cellular therapy and engineering, regenerative medicine and laboratory medicine.

The institute has been recognized for meeting very strict criteria, as well as for its advances in research.

Note originally published in: ediciónmedica.com

The District Institute of Science, Biotechnology and Innovation in Health (IDCBIS), has informed the entire community, both scientific and academic, that the Transfusion, Tissue and Cellular Medicine Research Group (GIMTTYC) has obtained the classification of "Transfusion, Tissue and Cellular Medicine" group. A1 research by the Ministry of Science, Technology and Innovation.

It should be noted that the group GIMTTYC is an interdisciplinary group with actions aimed at the development of three main areas in health: transfusion medicine, tissue and cellular therapy.

Its objective has been to identify health problems in the areas of transfusion medicine, tissue and cellular therapy in order to contribute in the solution through the development of research projects based on ethical criteria, that generate new knowledge, strengthen the training of researchers and consolidate research networks.

In interview with MEDICAL EDITION, Bernardo Camacho, director of the IDCBIS, said that "in the last call for applications more than 7,000 research groupsThe application is very rigorous, but in the end, a small group obtained the recognition, 849 groups remained".

Camacho explained that, "in group A there are 1,174, in group B there are 1,830 and in group C there are 2,376 groups. The A group has the least number of groups, but there are still 531 recognized groups."He added that "the A1 group is for research, which is like the top, in the sense that it is required to rigorously comply with the criteria to be in this group".

"In our case for the last four years we were in group C, but now we go up to A1 this is due to several factors, firstly having a senior researcher, international, scientific publications in high impact indexed journals," Camacho pointed out.

"For us that was very important because we were recognized in the field of health sciences, but we specifically have a research focus in the area of advanced cell therapies, among others. So we were recognized because we have carried out a great deal of scientific research and even original research in the focus that we have," said Camacho.

The director also explained that they train master's and doctoral students, and also have associate and senior researchers. "We are implementing the inclusion of more senior researchers."

"That designation is earned by all the achievements that the research group has made, but in October of the previous year we were recognized as a research center for the next five years, this due to the strength in information and scientific production, which performs the team of scientists who are working with us," Camacho has pointed out.

The IDCBIS research team plans to start clinical trials by the end of 2022.

January, 2022. Currently, the recovery time for fractures can take from 3 to 6 months. However, in some particular conditions, this time is extended to a year or more, because a large number of surgeries are required for patients to recover their mobility and normal rhythm of life. For this reason, researchers at the Tissue Engineering Unit of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) decided to use 3D printing to develop bone structures that can be applied in general and personalized medicine.

This is the first time that design, 3D printing and basic sciences have been combined to develop a device made with polylactic acid (PLA) for the repair of musculoskeletal tissue in Colombia. The results obtained in preclinical trials have shown greater efficacy compared to conventional methods. This is due to the device's architecture, which favors cell migration and its design prevents the muscle from invading it, thus contributing to tissue repair.

This research is led by scientists Ingrid Silva, William Cárdenas and Adriana Lara. The research is currently in the pre-clinical stage and the clinical phase is planned for the end of 2022 or beginning of 2023.

According to Dr. Bernardo Camacho, director of IDCBIS, "these types of research contributions are fundamental to contribute to improving the health of the country's population". He also explained that this project is part of the consolidation of a research and product development platform that has been developed at the Institute and which has allowed it to be recognized by the Ministry of Science, Technology and Innovation as a Research Center.

Other research conducted by the unit led by Dr. Ingrid Silva includes bioengineering of skin tissue and bone tissue, biological scaffolds for skin regeneration, cell encapsulation for advanced therapy, among others.

The meeting was held on December 9 and brought together the experiences of international donors and the expectations of potential donors to the Colombian program (DarCélulas).

Diciembre, 2021. DarCélulas is a research project executed by the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) with funding from the Science, Technology and Innovation Fund of the General System of Royalties and the District Administration of Bogota.

The purpose of the project is to create the first large database of blood-forming cell donors (also called stem cells), a registry of people willing to save the lives of people who do not know and have diseases such as leukemia.

Registries today exist in many countries around the world such as Japan and the United States; and in Latin America in Mexico, Argentina and Chile, among others. While in Colombia, the creation of the first registry was given in 2019 and with it, the realization of an annual event in which the updated information of the program is shared to the community of registered donors.

The first loyalty event was face-to-face at the Konrad Lorenz University in 2019, where the first balance and perspectives were presented. The 2020 event was virtual and was held with the slogan "compatible with life", in this version it was reported that the program would open its doors to other cities, in addition to Bogota, and experiences of international records were shown.

In the 2021 version, held on December 9, the protagonists were the potential donors who have registered in Colombia, who were the guests of honor at the event; on the other hand, an international story of a donor and a patient who were connected through a donation and were able to meet each other was shown. In addition, the expectations of potential donors who have registered in Bogota, Medellin, Cali and Barranquilla were made known.

At present, the program has surpassed the 3,000 people registered and more than 15,000 pre-registered.

Watch here #EventoDar2021:

Dermaglic provides an alternative to improve the quality of scars in patients with sequelae of burns and other traumas.

The skin is the most extensive organ of the human being, when a patient loses it massively there are great complications in the recovery, since only the epidermis has the capacity to regenerate it. When losing all the layers, the skin is reconstructed from collagen with a poor quality of healing, decreasing its function and affecting the aesthetics of patients.

As there are more cases of patients with large and deep burns, the challenge is to improve their quality of life, which is intimately related to the quality of the skin.

A challenge that in the XXI century is faced through tissue engineering with products such as Dermaglic, a class II substitute obtained from glycerolized skin of cadaveric donor which is processed through a chemical process of acceleration where a collagen and elastin sheet is obtained to contribute to the aesthetic and functional improvement of the burn.

Burns are the third cause of traumatic death in the pediatric population worldwide, posing a great challenge for public health that the District Tissue Bank is mitigating by making available to the country's surgeons this innovative alternative in Colombia that will contribute to the treatment of patients to improve the condition of their scars.

"This product that we are making available to patients today to help them in their recovery process is fundamental because it places Colombia at the forefront in the region, Dermaglic being the first of its kind in Latin America," explained Dr. Bernardo Camacho, director of the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) during the launch.

Dr. Alejandro Gomez, Secretary of Health of Bogota, highlighted the work done by the District Tissue Bank for the regeneration of skin of patients who have suffered severe burns and pointed out that the Mayor's Office of Bogota will continue to support the high quality research processes developed at IDCBIS.

The District Tissue Bank is a multi-tissue bank dedicated to donor selection, rescue, processing, preservation, storage and distribution of human tissues for implantation purposes. Currently, the bank processes skin, cornea and sclera, amniotic membrane and musculoskeletal tissue.

Líder-unidad-de-inmunohematología-avanzada-1200x563.jpg

The ISBT Working Party on Rare Donors is a prestigious global community with members in more than 18 countries.

Paula Andrea Gaviria, Leader of the Advanced Immunohematology Unit of IDCBIS, was selected by the "International Society of Blood Transfusion (ISBT)" as the most recent member of the "ISBT Working Party on Rare Donors", being the first Colombian and the third Latin American to achieve it.

The ISBT Working Party on Rare Donors aims to "provide a mechanism for collaboration between countries to enable the provision of rare blood products to patients in need".

According to the International Society of Blood Transfusion (ISBT), the group to which the IDCBIS collaborator now belongs is "a community eager to ensure that every patient who needs rare blood can receive it. This activity recognizes no political boundaries and is therefore all for the common good of patients all over the world".

The other two Latin American members of this group are Brazilian doctors Lilian Castilho and Silvano Wendel.

With this recognition, IDCBIS consolidates its position as the main actor in science and technology in the District and a reference for the country and the region.

September 10, 2021. Under resolution 1763 of 2021, the Ministry of Science, Technology and Innovation recognized the District Institute of Science Biotechnology and Innovation in Health (IDCBIS) as a research center for 5 years, a recognition that the Institute had received in 2019 for a period of one year.

In the resolution, the Ministry states the reasons why the IDCBIS is worthy of the designation, among them "high commitment to the development and implementation of strategies that are linked to the development of the country, articulated with the research policy from the research, training, technology transfer and generation of new knowledge axes.”.

According to IDCBIS director, Dr. Bernardo Camacho, "This recognition is the result of a work that began to take shape 20 years ago with the creation of the District Hemocenter and that four years ago materialized with the creation of the IDCBIS, joining the efforts of the Blood Bank, Tissue Bank and Cord Blood Bank with research and development of products in transfusion, tissue and cellular medicine, promoting the generation of knowledge and innovation in biomedical sciences through the articulation of actors in science and technology".

The analysis carried out by the technical area of the Knowledge Generation Directorate of the Ministry of Science corroborated that the Institute "...has the capacity to generate and manage the knowledge of the Ministry of Science...".demonstrates proper planning in research, administrative, service delivery, management and financial activities”.

On the other hand, it is noted that there were "a significant increase in the number of researchers linked to the center with respect to the first evaluation, which will result in scientific production, technological processes and contribute to the formation of new human capital.”.

Finally, MinCiencias evidenced IDCBIS's capacity to generate high impact products, relevant to the scientific and academic society, and to society in general. "The entire infrastructure and scientific capabilities of the Institute are at the service of the city and the country, which will allow the creation of new alliances that are in line with the District's Development Plan."explained Dr. Bernardo Camacho.

The Advanced Therapies Manufacturing Functional Unit (GMP Clean Room) will consolidate a research platform for advanced therapies and biotechnology drug production.

The project "Implementation of the Public Umbilical Cord Stem Cell Bank and a Cell Therapy Unit, Hemocentro Distrital, District Health Secretariat, Bogotá", financed by the General Royalties System and the District Health Financial Fund of Bogotá, included the design and installation of a Clean Room or integrated unit for the manufacture of products for advanced therapies, umbilical cord blood processing and research laboratories.

This laboratory, called the Clean Room, due to its maximum environmental control conditions (temperature, humidity, air pressure and contamination), is the only one of this size (280m2 approximately) and degree of complexity in Colombia. These state-of-the-art facilities put the Institute in a position to strengthen national and international scientific cooperation agreements and position it as a leader in the region in innovation in cell therapy, gene therapy and tissue engineering.

The start-up of this Clean Room is an achievement for science in Bogota and the country and will be used, among others, for the development of new medical biotechnology products, including tissue processing, the manufacture of products for cell and gene therapy, and the processing of blood precursor cells for transplantation.

All this infrastructure placed at the service of science and the development of Bogota and the country is the result of the work that the IDCBIS (formerly the District Hemocenter) has been carrying out for several years, in which a team of highly trained researchers has been consolidated, annually accumulating new patents, publications in scientific journals and doctoral and master's theses.

The start-up of this Clean Room is a critical route to initiate the production in controlled pharmaceutical environments of advanced and innovative medicines that will later be subjected to clinical trials to determine their safety and clinical efficacy. Ultimately, this new phase constitutes a strong commitment by the Health Sector to promote science and technology.
biomedical research with a common goal, to find the solution to complex chronic and degenerative diseases that afflict our population.

The faces behind the implementation of the GMP Clean Room: Maryuris Milore, a girl from Barranquilla, who due to medullary aplasia (a disease where the bone marrow stops producing blood components), for several years was subjected to painful therapies and treatments, until in 2017 she received a transplant of blood-forming cells processed at the Public Cord Blood Bank IDCBIS. From the transplant Maryuris, regained her full health and was able to return to her favorite activities such as skating and playing.

This is just one of the many research projects that will be enhanced and improved with the installation of the Advanced Therapies Manufacturing Functional Unit (GMP Clean Room), a state-of-the-art infrastructure that will allow moving from the research phase to the application phase of medical products and technologies that are already being developed at the Institute, where the scientific method is used to solve problems that are still unsolved.

Who will benefit from the products obtained in the future in the IDCBIS Clean Room laboratories?

1. Patients with severe hematological diseases such as leukemias and lymphomas.
2. Patients with primary immunodeficiencies
3. Patients with inborn errors of metabolism
4. Cancer immunotherapy
5. Patients with complex orthopedic conditions.
6. Patients with autoimmune diseases
7. Patients with neurodegenerative diseases

Older Posts

Blog

Primera patente concedida al IDCBIS en el uso de células mesenquimales

Banco Distrital de Sangre IDCBIS de Bogotá Certificado con los Más Altos Estándares de Calidad Europeos

The District strengthens health research with the cooperation agreement between the Universidad Nacional de Colombia - Bogotá and the Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud.

IDCBIS obtains A1 research group classification by Minciencias

The institute has been recognized for meeting very strict criteria, as well as for its advances in research.

Scientists use 3D printing for bone repair to improve quality of life for patients in Bogota

Potential cell donors for patients with blood diseases such as lucemia meet in Bogota

The District Tissue Bank IDCBIS launches Dermaglic, an innovative alternative in Colombia to help burn patients.

Leader of Advanced Immunohematology at IDCBIS becomes the first Colombian to be a member of the "ISBT Working Party on Rare Donors".

The Ministry of Science recognized the District Institute of Science, Biotechnology and Innovation in Health (IDCBIS) as a Research Center for 5 years.

The district institute of science, biotechnology and innovation in health puts at the service of science and health the first gmp clean room in Bogota.

The Advanced Therapies Manufacturing Functional Unit (GMP Clean Room) will consolidate a research platform for advanced therapies and biotechnology drug production.

Who will benefit from the products obtained in the future in the IDCBIS Clean Room laboratories?

Primera patente concedida al IDCBIS en el uso de células mesenquimales

Bogotá da un paso adelante de mano de la ciencia y la investigación con el proyecto pionero en salud “Donantes Únicos”

¿Por qué son tan importantes las donaciones O- en este momento?

¿Cómo surgieron los bancos de sangre?

Banco Distrital de Sangre IDCBIS de Bogotá Certificado con los Más Altos Estándares de Calidad Europeos

IDCBIS

BANCO DISTRITAL DE SANGRE

Instalaciones:

Phone:

PASIÓN POR LA CIENCIA Y LA VIDA